Yan Huang

Yan Huang

Auto-generated profile, based on publicly available information

Yan Huang

Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Journal of Cell Biology
Verified
Journal Article
Open access
KHKai He
Kai He
XSXiaobo Sun
Xiaobo Sun
CCChuan Chen
Chuan Chen
SLSan Luc
San Luc
JRJielu Hao Robichaud
Jielu Hao Robichaud
JHJinghua Hu
Jinghua Hu
Tubulin polyglutamylation is a posttranslational modification that occurs primarily along the axoneme of cilia. Defective axoneme polyglutamylation impairs cilia function and has been correlated with ciliopathies, including Joubert Syndrome (JBTS). However, the precise mechanisms regulating proper axoneme polyglutamylation remain vague. Here, we show that cyclin-dependent kinase 6 (CDK6), but not its paralog CDK4, localizes to the cilia base and suppresses axoneme polyglutamylation by phosphorylating RAB11 family interacting protein 5 (FIP5) at site S641, a critical regulator of cilia import of glutamylases. S641 phosphorylation disrupts the ciliary recruitment of FIP5 and its association with RAB11, thereby reducing the ciliary import of glutamylases. Encouragingly, the FDA-approved CDK4/6 inhibitor Abemaciclib can effectively restore cilia function in JBTS cells with defective glutamylation. In summary, our study elucidates the regulatory mechanisms governing axoneme polyglutamylation and suggests that developing CDK6-specific inhibitors could be a promising therapeutic strategy to enhance cilia function in ciliopathy patients.

25 November 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CCChuan Chen
Chuan Chen
ZWZhifei Wang
Zhifei Wang
YGYue Gao
Yue Gao
MEMadilyn R. Ellis
Madilyn R. Ellis
BJBiyun Ji
Biyun Ji
Kun LingKun Ling
Kun Ling
Key Points: Inositol polyphosphate-5-phosphatase E (INPP5E) and type Ig phosphatidylinositol-4-phosphate 5-kinase (PIPKIγ) coordinated the homeostasis of phosphatidylinositol-4-phosphate and phosphatidylinositol-4,5-bisphosphate in primary cilia. Modulating INPP5E or PIPKIγ activity changed the level of polycystin-1 and polycystin-2 in primary cilia. INPP5E inhibition increased the hypomorphic PKD1 variants (PC1-R3277C) in cilia and reduced cystogenesis in the kidney in vitro . Background: Autosomal dominant polycystic kidney disease is mainly caused by mutations in PKD1 and PKD2 , which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC1 and PC2 assemble a cation channel complex enriched in primary cilium, a sensory organelle associated with various developmental diseases, including polycystic kidney disease (PKD). Accumulating evidence supports the necessity of functional polycystin (PC) complex in cilia to prevent cystogenesis in the kidney, indicating that improving their ciliary levels may ameliorate defects underlying PKD pathogenesis. Yet, molecular mechanisms underlying the ciliary targeting and homeostasis of the PC complex are not fully understood. Methods: Indirect immunofluorescence microscopy was used to monitor ciliary levels of PC1 and PC2 in renal epithelial cells. Electrophysiology analysis in oocytes was used to determine the channel activity of the PC complex. Cystogenesis in the kidney was measured using in vitro 3D-Matrigel cell models and ex vivo mouse embryonic kidney models. Results: Suppressing inositol polyphosphate-5-phosphatase E (INPP5E) or activating type Ig phosphatidylinositol-4-phosphate 5-kinase raised ciliary levels of the PC complex in both normal renal epithelial cells and cells carrying autosomal dominant polycystic kidney disease mutations that interrupt the trafficking of PCs into cilia, including GANAB inactivation and the trafficking PKD1 mutation p.Arg3277Cys (RC). PC1 RC formed a complex with PC2 and exhibited normal channel activity in vitro . An INPP5E that increases PC1 and PC2 in cilia, suppressed in vitro forskolin-induced cystogenesis of inner medullary collecting duct epithelial cell line 3 cells in 3D Matrigel and ex vivo cyst formation in embryonic Pkd1 RC/RC mouse kidneys. Conclusions: Our results demonstrated that increasing the ciliary level of PCs, by manipulating a ciliary phosphoinositide signaling axis, enhanced the functionality of PCs and suppressed cystogenesis of renal epithelial cells in vitro .

29 April 2025 in American Journal of Nephrology
Verified
Journal Article
Open access
VDVincent Dumont
Vincent Dumont
SMSandrine Meurisse
Sandrine Meurisse
KVKatleen Verdonck
Katleen Verdonck
VSValérie Salgues
Valérie Salgues
TRTiffany Robert
Tiffany Robert
DCDaniel Comas
Daniel Comas
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder that is characterized by the development of fluid-filled kidney cysts, which often lead to kidney failure. The vasopressin receptor 2 antagonist, tolvaptan, is the only approved treatment that slows the progression of ADPKD. There is an unmet need for treatment options for patients with ADPKD because tolvaptan has limited efficacy and non-negligible side effects. In vitro and in vivo data suggest that inhibition of the cystic fibrosis transmembrane conductance regulator (CFTR) may be a suitable approach to treating ADPKD. Here, we assessed the capacity of GLPG2737, a CFTR inhibitor, to inhibit cyst growth in preclinical models of ADPKD. Methods: We investigated the ability of GLPG2737 to modulate CFTR activity in mouse kidney inner medullary collecting duct (mIMCD-3) epithelial cells by measuring chloride flux, and to prevent cyst growth in mIMCD-3 cells, cells from human ADPKD kidney donors, and metanephric organ cultures (MOCs). We assessed cyst volume, kidney weight or volume, and blood urea nitrogen (BUN) in two mouse ADPKD models (Pkd1 kidney-specific knockout mouse model; Pkd1RC/RC mouse model) that received GLPG2737, tolvaptan, or their combination. Statistical tests used for data analysis were based on the normality and variance of the data. Results: GLPG2737 inhibited chloride flux in mIMCD-3 cells with an IC50 of 2.41 µM. In a 3D assay, GLPG2737 inhibited cyst growth in both wild-type (IC50 = 2.36 µM) and Pkd1 knockout (IC50 = 2.5 µM) mIMCD-3 cells. Preincubation of human ADPKD kidney cells with 10 µM of GLPG2737, 10 µM of tolvaptan, or their combination prevented forskolin-induced cyst growth by 40%, 29%, and 70%, respectively. Furthermore, 10 µM of GLPG2737 inhibited cyst growth in MOCs, decreasing the cyst area by 67% and the number of cysts per area by 46% after 6 days of culture. In both in vivo models, GLPG2737, tolvaptan, or their combination improved the projected cyst volume. In the Pkd1RC/RC model, GLPG2737 also improved the total kidney volume normalized to tibia length (LnTKV) and BUN, while tolvaptan improved the LnTKV and fibrosis but did not lower BUN at sacrifice. The combination reduced all parameters measured in the Pkd1RC/RC model, including cyclic adenosine monophosphate (cAMP) content in the kidneys. Conclusions: Our findings in preclinical models provide evidence of the therapeutic potential of CFTR inhibition, and its possible combination with tolvaptan. The present work shows that targeting CFTR is a valid strategy to slow ADPKD progression.

14 September 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
YCYingshu Cao
Yingshu Cao
XSXiaobo Sun
Xiaobo Sun
YHYan Huang
Yan Huang
CCChuan Chen
Chuan Chen
BJBiyun Ji
Biyun Ji
KHKai He
Kai He
Key Points: CDK6 was robustly upregulated in cyst-lining epithelial cells. The CDK4/6 inhibitor abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin dosage in autosomal dominant polycystic kidney disease renal epithelial cells. Abemaciclib arrested or reversed cyst progression in a sex-specific manner with greater efficacy and safety than tolvaptan in an autosomal dominant polycystic kidney disease mouse model. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disorder leading to kidney failure. Tolvaptan, the only US Food and Drug Administration–approved therapy, modestly slows disease progression but is limited by significant adverse effects, highlighting the need for more effective and better-tolerated treatments. Ciliary polycystins are central to ADPKD pathogenesis. We previously demonstrated that a ciliary base–localized pool of CDK6 restricts ciliary polycystin abundance by suppressing axonemal polyglutamylation. However, whether CDK6 inhibition can restore polycystin function and suppress ADPKD progression in vivo remains unknown. Methods: Abemaciclib was tested in in vitro 3D cyst assays and ex vivo metanephric organ cultures. In vivo efficacies of early- and late-stage intervention were assessed in F1(129/B6) Pkd1 R3277C/R3277C mice receiving daily abemaciclib. Tolvaptan served as a therapeutic control. Cyst burden, fibrosis in the kidneys, kidney function, and primary cilia of renal epithelial cells were analyzed at study end points. Results: CDK6 was prominently upregulated in cyst-lining cells in human and murine polycystic kidney disease kidneys. At doses substantially lower than those used in oncology, abemaciclib robustly suppressed cyst growth in vitro and ex vivo . In vivo , long-term early treatment arrested cyst progression more effectively than tolvaptan without detectable toxicity. Late intervention largely halted cyst growth in female mice and reversed cyst progression in male mice. Mechanistically, abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin levels. Conclusions: Abemaciclib had greater therapeutic efficacy and tolerability than tolvaptan in this preclinical model, largely driven by CDK6 inhibition–mediated restoration of axonemal polyglutamylation and increased ciliary polycystin abundance.